https://ogma.newcastle.edu.au/vital/access/ /manager/Index ${session.getAttribute("locale")} 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42660 Wed 31 Aug 2022 13:09:31 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53452 Tue 28 Nov 2023 10:10:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53267 Mon 20 Nov 2023 12:49:07 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:52486 Fri 13 Oct 2023 10:03:34 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53590 PD >NG, p=0.0046). Post-hoc analysis indicated significantly higher plasma NfL levels in the T2D [12.4 (5.21) pg/mL] group than in the PD [10.2 (4.13) pg/mL] and NG [8.37 (5.65) pg/mL] groups. The relationship between diabetes status and NfL remained significant after adjusting for age, sex, BMI, HOMA-IR and physical activity (adjusted r2 = 0.271, p = 0.035). Conclusions: These results show biomarker evidence of neurodegeneration in adults at risk or with T2D. Larger sample size and longitudinal analysis are required to better understand the application of NfL in people with risk and overt T2D.]]> Fri 08 Dec 2023 15:47:18 AEDT ]]>